Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Adobe

- PMLiVE

Emergency authorisation for Pfizer/BioNTech vaccine expanded in the US

Data from a study involving 12 to 15 year olds has also been submitted to the EMA for potential approval

- PMLiVE

Pfizer, BioNTech file for full US approval of COVID-19 vaccine

Pfizer chief executive Albert Bourla said last week the company is on track to supply 2.7bn doses in 2021

- PMLiVE

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Trial pause follows reports of three cases of peripheral neuropathy in phase 1 study

- PMLiVE

BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021

BioNTech’s CEO Ugur Sahin said increase in manufacturing will allow for this target to be met

- PMLiVE

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Full-year guidance for BioNTech-partnered vaccine increased to $26bn

- PMLiVE

Pfizer acquires Amplyx Pharmaceuticals, including new potential class of therapeutics

Drug could treat life-threatening antifungal-resistant infections

- PMLiVE

Pfizer CEO says oral COVID-19 pill could be ready by the end of the year

Company initiated a phase 1 study of the drug last month

Lucid Group is building its data analytics capability

Lucid Group is building a new data analytics capability into its teams with the appointment of Darren Selmes as its new analyst. This appointment signals the start of a stronger...

Lucid Group Communications Limited

- PMLiVE

Lucid Group promotes Clare Reynolds to Director of Business Development and Commercial Integration

As Lucid continues to evolve, its people have remained at the heart of its success. Clare Reynolds has played a key part in Lucid’s journey for nearly 12 years, during...

Lucid Group Communications Limited

Lucid Group Bolster its Senior Leadership Team

Lucid Group are delighted to welcome Jo Troman to the role of Managing Partner for team Origins. Jo has a wealth of industry experience from both client and agency sides....

Lucid Group Communications Limited

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in adolescents

Vaccine was found to be safe and effective in adolescents aged 12 to 15 years old

- PMLiVE

BioNTech forecasts €9.8bn in sales of Pfizer-partnered COVID-19 vaccine in 2021

Company also raised full year manufacturing capacity target for vaccine to 2.5 billion doses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links